Published in J Urol on July 01, 2003
Image-guided cancer surgery using near-infrared fluorescence. Nat Rev Clin Oncol (2013) 3.01
Imaging and photodynamic therapy: mechanisms, monitoring, and optimization. Chem Rev (2010) 2.44
Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol (2010) 2.13
Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles. Eur Urol (2009) 1.79
Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol (2012) 1.63
Best practice in the treatment of nonmuscle invasive bladder cancer. Ther Adv Urol (2012) 1.13
New optical imaging technologies for bladder cancer: considerations and perspectives. J Urol (2012) 1.12
Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015. Can Urol Assoc J (2016) 1.08
Critical evaluation of urinary markers for bladder cancer detection and monitoring. Rev Urol (2008) 1.05
High-risk non-muscle-invasive bladder cancer: update for a better identification and treatment. World J Urol (2012) 0.97
Application of new technology in bladder cancer diagnosis and treatment. World J Urol (2009) 0.91
Mapping of oxidative stress responses of human tumor cells following photodynamic therapy using hexaminolevulinate. BMC Genomics (2007) 0.82
The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer - A New Analysis. Bladder Cancer (2016) 0.82
HAL fluorescence cystoscopy and TURB one year of Romanian experience. J Med Life (2010) 0.79
Efficacy and safety of hexaminolevulinate fluorescence cystoscopy in the diagnosis of bladder cancer. Korean J Urol (2012) 0.79
Vision 20/20: Molecular-guided surgical oncology based upon tumor metabolism or immunologic phenotype: Technological pathways for point of care imaging and intervention. Med Phys (2016) 0.76
Early detection of urothelial premalignant lesions using hexaminolevulinate fluorescence cystoscopy in high risk patients. J Transl Med (2010) 0.76
[Not Available]. Can Urol Assoc J (2014) 0.75
Hexaminolevulinate hydrochloride in the detection of nonmuscle invasive cancer of the bladder. Ther Adv Urol (2015) 0.75
Spectrophotometric photodynamic detection involving extracorporeal treatment with hexaminolevulinate for bladder cancer cells in voided urine. J Cancer Res Clin Oncol (2017) 0.75
False-positive lesions detected by fluorescence cystoscopy: any association with p53 and p16 expression? World J Urol (2006) 0.75
A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol (2009) 3.59
Long-term distress after radical prostatectomy versus watchful waiting in prostate cancer: a longitudinal study from the Scandinavian Prostate Cancer Group-4 randomized clinical trial. Eur Urol (2013) 2.84
Processes and outcomes of HIV serostatus disclosure to sexual partners among people living with HIV in Uganda. AIDS Behav (2007) 2.78
Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med (2010) 2.62
Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. J Clin Oncol (2011) 2.60
MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. Am J Surg Pathol (2005) 2.51
The Study of Active Monitoring in Sweden (SAMS): a randomized study comparing two different follow-up schedules for active surveillance of low-risk prostate cancer. Scand J Urol (2013) 2.29
Should molecular testing be required for diagnosing synovial sarcoma? A prospective study of 204 cases. Cancer (2003) 2.28
Identification of cancer stem cells in Ewing's sarcoma. Cancer Res (2009) 2.15
Urinary bladder cancer treated with radical cystectomy: perioperative parameters and early complications prospectively registered in a national population-based database. Scand J Urol (2014) 2.07
Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma. Eur Urol (2008) 2.06
Guidelines on bladder cancer. Eur Urol (2002) 1.97
Pleomorphic liposarcoma: clinicopathologic, immunohistochemical, and follow-up analysis of 63 cases: a study from the French Federation of Cancer Centers Sarcoma Group. Am J Surg Pathol (2002) 1.95
Gender differences in delays in diagnosis and treatment of tuberculosis. Health Policy Plan (2007) 1.94
Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. Am J Surg Pathol (2007) 1.88
EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. Genes Dev (2010) 1.81
Orgasm-associated urinary incontinence and sexual life after radical prostatectomy. J Sex Med (2011) 1.73
Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines. J Urol (2007) 1.70
Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin Cancer Res (2007) 1.68
On the selectivity of 5-aminolevulinic acid-induced protoporphyrin IX formation. Curr Med Chem Anticancer Agents (2004) 1.65
The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies. Haematologica (2006) 1.59
Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. BJU Int (2005) 1.58
Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma. Cancer Res (2006) 1.52
Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res (2006) 1.52
Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur Urol (2011) 1.51
Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol (2008) 1.50
Defecation disturbances after cystectomy for urinary bladder cancer. BJU Int (2010) 1.46
Barriers and facilitators to provide effective pre-hospital trauma care for road traffic injury victims in Iran: a grounded theory approach. BMC Emerg Med (2010) 1.43
[Recent entities in soft tissue tumor pathology. Part 2]. Ann Pathol (2003) 1.42
Clinicopathologic and molecular genetic characterization of low-grade fibromyxoid sarcoma, and cloning of a novel FUS/CREB3L1 fusion gene. Lab Invest (2005) 1.41
Inguinal hernia after radical prostatectomy for prostate cancer: results from a randomized setting and a nonrandomized setting. Eur Urol (2010) 1.39
'Pregnancy comes accidentally--like it did with me': reproductive decisions among women on ART and their partners in rural Uganda. BMC Public Health (2011) 1.38
Ear to the ground: listening to farm dwellers talk about the experience of becoming lay health workers. Health Policy (2004) 1.36
Primary intrathoracic synovial sarcoma: a clinicopathologic study of 40 t(X;18)-positive cases from the French Sarcoma Group and the Mesopath Group. Am J Surg Pathol (2005) 1.35
Mineral composition of organically grown wheat genotypes: contribution to daily minerals intake. Int J Environ Res Public Health (2010) 1.34
Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol (2009) 1.32
Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol (2004) 1.28
Bacteria capture iron from heme by keeping tetrapyrrol skeleton intact. Proc Natl Acad Sci U S A (2009) 1.27
Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue. Kidney Int (2005) 1.27
Array CGH analysis in primary gastrointestinal stromal tumors: cytogenetic profile correlates with anatomic site and tumor aggressiveness, irrespective of mutational status. Genes Chromosomes Cancer (2007) 1.27
Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol (2013) 1.25
Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations. Eur Urol (2010) 1.24
Adult-type rhabdomyosarcoma: analysis of 57 cases with clinicopathologic description, identification of 3 morphologic patterns and prognosis. Am J Surg Pathol (2009) 1.24
Zinc-based fixative improves preservation of genomic DNA and proteins in histoprocessing of human tissues. Lab Invest (2003) 1.23
The chick embryo and its chorioallantoic membrane (CAM) for the in vivo evaluation of drug delivery systems. Adv Drug Deliv Rev (2007) 1.20
Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule. J Mol Biol (2008) 1.19
Epithelioid sarcoma: a clinicopathologic and immunohistochemical analysis of 106 cases from the French sarcoma group. Am J Clin Pathol (2009) 1.18
MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone. Mod Pathol (2011) 1.17
A subgroup of malignant fibrous histiocytomas is associated with genetic changes similar to those of well-differentiated liposarcomas. Cancer Genet Cytogenet (2002) 1.17
The TPTE gene family: cellular expression, subcellular localization and alternative splicing. Gene (2003) 1.16
Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer -- Nordic cystectomy trial 2. Scand J Urol Nephrol (2002) 1.14
Positron emission tomography with C11-acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy. Urology (2006) 1.14
Impact of thawing on RNA integrity and gene expression analysis in fresh frozen tissue. Diagn Mol Pathol (2009) 1.13
A second-look TUR in T1 transitional cell carcinoma: why? Eur Urol (2004) 1.13
What do young adults know about the HIV/AIDS epidemic? Findings from a population based study in Karachi, Pakistan. BMC Infect Dis (2009) 1.12
Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88. J Clin Oncol (2004) 1.12
Stimulation of anti-tumor immunity by photodynamic therapy. Expert Rev Clin Immunol (2011) 1.11
Primary clear cell sarcoma of the ileum: an uncommon and misleading site. Virchows Arch (2005) 1.10
A comparative study of three different PCR assays for detection of Mycoplasma genitalium in urogenital specimens from men and women. J Med Microbiol (2008) 1.09
Monophasic fibrous and poorly differentiated synovial sarcoma: immunohistochemical reassessment of 60 t(X;18)(SYT-SSX)-positive cases. Am J Surg Pathol (2002) 1.09
Proteomic analysis of urinary biomarker candidates for nonmuscle invasive bladder cancer. Proteomics (2011) 1.09
Molecular characterization by array comparative genomic hybridization and DNA sequencing of 194 desmoid tumors. Genes Chromosomes Cancer (2010) 1.09
Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics. Am J Pathol (2010) 1.09
Mozambican midwives' views on barriers to quality perinatal care. Health Care Women Int (2006) 1.08
Photodynamic therapy for polypoidal choroidal vasculopathy. Prog Retin Eye Res (2013) 1.08
5-Aminolevulinic acid derivatives in photomedicine: Characteristics, application and perspectives. Photochem Photobiol (2007) 1.07
ASK1 (MAP3K5) as a potential therapeutic target in malignant fibrous histiocytomas with 12q14-q15 and 6q23 amplifications. Genes Chromosomes Cancer (2004) 1.07
Understanding caretakers' dilemma in deciding whether or not to adhere with referral advice after pre-referral treatment with rectal artesunate. Malar J (2010) 1.06
Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer. Am J Pathol (2012) 1.04
Digestive PEComas: a solution when the diagnosis fails to "fit". Ann Diagn Pathol (2004) 1.04
Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane-associated N-terminal domain. Protein Sci (2004) 1.04
Rhabdomyosarcoma: value of myogenin expression analysis and molecular testing in diagnosing the alveolar subtype: an analysis of 109 paraffin-embedded specimens. Cancer (2004) 1.04
Mechanisms of bacillus Calmette-Guerin mediated natural killer cell activation. J Urol (2004) 1.03
Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer. Am J Pathol (2012) 1.03
Functional therapy for children with cerebral palsy: an ecological approach. Dev Med Child Neurol (2005) 1.02
Photodynamic therapy of skin cancer: controlled drug delivery of 5-ALA and its esters. Adv Drug Deliv Rev (2004) 1.02
Antibiotic use, resistance development and environmental factors: a qualitative study among healthcare professionals in Orissa, India. BMC Public Health (2010) 1.02
Outcome analysis of fornix ruptures in 162 consecutive patients. J Endourol (2010) 1.02
Alpha-methyl CoA racemase expression in renal cell carcinomas. Hum Pathol (2006) 1.02
Inflammatory malignant fibrous histiocytomas and dedifferentiated liposarcomas: histological review, genomic profile, and MDM2 and CDK4 status favour a single entity. J Pathol (2004) 1.02
Photoeradication of Helicobacter pylori using 5-aminolevulinic acid: preliminary human studies. Lasers Surg Med (2002) 1.01
Osteoid osteoma and osteoid osteoma-mimicking lesions: biopsy findings, distinctive MDCT features and treatment by radiofrequency ablation. Eur Radiol (2010) 1.01
The importance of groundwater discharge for plant species number in riparian zones. Ecology (2007) 1.00
Evaluation of the CFP-substrate-YFP system for protease studies: advantages and limitations. Biotechniques (2004) 1.00
Efficacy and safety of short-term genistein intervention in patients with localized prostate cancer prior to radical prostatectomy: a randomized, placebo-controlled, double-blind Phase 2 clinical trial. Nutr Cancer (2011) 0.99
Health-related quality of life among patients with ichthyosis. Eur J Dermatol (2004) 0.99
Barriers of mistrust: public and private health sectors' perceptions of each other in Madhya Pradesh, India. Qual Health Res (2008) 0.99
Strong smooth muscle differentiation is dependent on myocardin gene amplification in most human retroperitoneal leiomyosarcomas. Cancer Res (2009) 0.99
Short- and long-term prognostic value of postoperative cardiac troponin I concentration in patients undergoing coronary artery bypass grafting. Anesthesiology (2003) 0.99
Focal amplifications are associated with high grade and recurrences in stage Ta bladder carcinoma. Int J Cancer (2010) 0.99
Coactivated platelet-derived growth factor receptor {alpha} and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma. Cancer Res (2010) 0.98
Human herpesvirus 8 immunostaining: a sensitive and specific method for diagnosing Kaposi sarcoma in paraffin-embedded sections. Am J Clin Pathol (2004) 0.98
Carotenoids in sea buckthorn ( Hippophae rhamnoides L.) berries during ripening and use of pheophytin a as a maturity marker. J Agric Food Chem (2009) 0.98
Vascular regrowth following photodynamic therapy in the chicken embryo chorioallantoic membrane. Angiogenesis (2010) 0.97
In vitro and in vivo photocytotoxicity of boron dipyrromethene derivatives for photodynamic therapy. J Med Chem (2010) 0.97